Vir Biotechnology and Gilead Agree to Develop Three Tumor-Targeting Candidates

The collaboration will discover and engineer three PRO-XTEN dual-masked T-cell engager development candidates targeting selected solid tumor-associated antigens. Gilead will have an exclusive license to…